Pomerantz LLP is investigating Ionis Pharmaceuticals and its executives for possible securities fraud following the failure of the Phase-3 CARDIO-TTransform trial for Wainua, a treatment for amyloid cardiomyopathy. The trial's failure caused Ionis's stock to drop nearly 24% on July 9, 2026. The investigation aims to determine if the company engaged in unlawful business practices. Investors affected are encouraged to contact Pomerantz for potential class action participation.
Advance Auto Parts saw its price target cut from $62 to $43 by Truist after reporting Q2 2026 results with a 0.5% sales decline and weaker-than-expected DIY segment sales. Although adjusted EPS beat estimates at $1.03, this was boosted by a $0.31 tar...
BMO Capital initiated an "Outperform" rating on D-Wave Quantum despite flat Q2 revenues and widening losses, signaling confidence in the company's growth potential. The firm's first-half bookings surged 1,120%, showing strong but volatile demand in q...
South Korea's largest crypto exchange, Upbit, will list eight new trading pairs involving four tokens: Biconomy (BICO), Bubblemaps (BMT), Nillion (NIL), and ETHGas (GWEI). Starting August 21, these tokens will be tradable against Bitcoin and Tether, ...
QNB Corp. has moved its stock listing from the OTC exchange to the Nasdaq Capital Market and completed a public offering raising approximately $48.3 million by selling 1.23 million shares, including an overallotment option. The funds will be used for...
During the Coldcard hardware wallet security crisis, 13 major bitcoin wallet manufacturers responded with different speeds and communication styles on social media. Some, like Bitkey and Blockstream Jade, quickly reassured users and provided detailed...
